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Abstract 
Aims/Introduction: Painful diabetic peripheral neuropathy (PDPN) has a significant impact on the 
patient’s quality of life. The prevalence of PDPN in the Middle East and North Africa (MENA) region 
has been reported to be almost double that of populations in the UK. We sought to determine the 
prevalence of PDPN and its associated factors in T2DM patients attending secondary care in Qatar. 
Materials and Methods: This is a cross-sectional study of 1095 participants with T2DM attending 
Qatar’s two national diabetes centers. PDPN and impaired vibration perception on the pulp of the 
large toes were assessed using the DN4 questionnaire with a cut-off ≥4 and the Neurothesiometer 
with a cut-off ≥15V, respectively. 
Results: The prevalence of PDPN was 34.5% (95% CI: 31.7%-37.3%), but 80% of these patients had 
not previously been diagnosed or treated for this condition. Arabs had a higher prevalence of PDPN 
compared to South Asians (P<0.05). PDPN was associated with impaired vibration perception 
AOR=4.42 (95%CI: 2.92-6.70), smoking AOR=2.43 (95%CI: 1.43-4.15), obesity AOR=1.74 (95%CI: 1.13-
2.66), being female AOR=1.65 (95%CI: 1.03-2.64) and duration of diabetes AOR=1.08 (95%CI: 1.05-
1.11). Age, poor glycemic control, hypertension, physical activity and proteinuria showed no 
association with PDPN.  
Conclusions: PDPN occurs in 1/3 of T2DM patients attending secondary care in Qatar, but the 
majority have not been diagnosed. Arabs are at higher risk for PDPN. Impaired vibration perception, 
obesity and smoking are associated with PDPN in Qatar. 
 
Keywords: Painful diabetic peripheral neuropathy; Obesity; Type 2 Diabetes 
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Introduction 
Painful diabetic peripheral neuropathy (PDPN) has a significant impact on the patient’s quality of 
life1-3 as it is accompanied by depression, anxiety and sleep disturbance2. Estimates of the 
prevalence of PDPN in patients with T2DM vary and range from 17.9%-65.3%1, 4-6. In a large 
population-based study (n=15,692) from the UK 4, we previously showed that PDPN occurred in 
21.5% of patients with T2DM and was more common in South Asians. In the Middle East and North 
Africa (MENA) region, Jambart et al. 5 reported a much higher prevalence of PDPN of 61.3% in Egypt, 
57.5% in Jordan, 53.9% in Lebanon and 37.1% in the United Arab Emirates.  
Despite having a serious impact on the patient’s quality of life, PDPN is underdiagnosed and 
undertreated7, 8. Patients with painful symptoms are often unaware that the pain is related to 
diabetes and do not report it to their clinician8, 9. Screening patients at high risk for PDPN should 
allow timely identification and treatment. Previous studies have shown that older age, a longer 
duration of diabetes, being female and the presence of diabetic peripheral neuropathy (DPN) 
increases the risk for PDPN1, 4-6, 10, 11. Additionally, obesity1, 5, 7, 12, low physical activity13, 14, smoking4, 
12, poor glycemic control 15, 16, low HDL cholesterol1, raised LDL cholesterol, triglycerides and 
creatinine13, are also independent risk factors of PDPN. 
The aim of this study was to establish the prevalence of PDPN in patients with T2DM in secondary 
care in Qatar and explore the association with ethnicity and risk factors for this condition. We have 
undertaken a large cross-sectional cohort study using DN4, a validated and highly sensitive and 
specific questionnaire for the diagnosis of PDPN17. 
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Materials and Methods 
This is a cross-sectional cohort study. Patients with diabetes aged 18 years and above were recruited 
from the two National Diabetes & Endocrine Centers in Qatar, Hamad General Hospital and Al-
Wakra Hospital. Participating clinicians reported on all patients satisfying the inclusion criteria, 
examined between March 2017 to March 2018. No refusals were recorded as the procedure was 
quick, simple and potentially valuable to the patient health. Participants with other causes of 
neuropathy including vitamin B12 deficiency, hypothyroidism, HIV infection, leprosy, hepatitis C and 
chemotherapy were excluded from the study. We enrolled 1,163 individuals and after excluding 66 
patients with T1DM and 2 patients who did not complete the assessments were left with a sample 
size of 1,095.  
This study was approved by the Institutional Review Board (IRB) of WCM-Q and HMC and all 
participants gave informed consent to take part in the study. The research adhered to the tenets of 
the declaration of Helsinki. 
 
Demographic and metabolic measures 
Age, gender, duration of diabetes, height, weight and BMI were recorded. Ethnicity was categorized 
as Qatari Arabs, other Arabs, South Asians, and other ethnic groups. The average of two readings of 
the systolic (SBP) and diastolic (DBP) blood pressure taken from the subject’s left arm while seated 
with his/her arm at heart level, using a standard zero mercury sphygmomanometer after 10-15 
minutes of rest was obtained. A non-fasting blood sample of 10 ml was collected through 
venepuncture from each participant into vacutainer tubes containing EDTA. The samples were kept 
at room temperature and transported within 2 hours to a central certified laboratory at Hamad 
General Hospital, HMC, Doha, Qatar. Glycated haemoglobin (HbA1c), total cholesterol, HDL, LDL and 
triglycerides were measured by an autoanalyzer (Hitachi 747 autoanalyzer, Japan). Urinary albumin 
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and creatinine levels were assessed on a random spot urine sample to evaluate the albumin-to-
creatinine ratio (ACR). Patients with an HbA1c ≥9% were considered to be poorly controlled. 
Hypertension was defined according to either an average systolic blood pressure (SBP) ≥ 140 mmHg 
and/or the use of antihypertensive medication, as described in the WHO/ISH Guidelines18. Current 
cigarette smoking was defined as having smoked at least one cigarette every day for 30 days 
preceding the study visit. Physical activity was defined as doing physical activity including walking for 
30 minutes or more in a day for at least 3 times a week. Obesity was classified according to WHO 
criteria19 with a BMI ≥30 Kg/m2. Proteinuria was defined as an ACR >30mg/g. 
 
Painful diabetic peripheral neuropathy assessment 
The Douleur Neuropathique en 4 (DN4) questionnaire has been validated for painful diabetic 
peripheral neuropathy (PDPN)20 and can distinguish between nociceptive and neuropathic pain21. It 
consists of 10 questions: 7 questions relating to the pain description (burning, painful cold, electric 
shocks) and associated abnormal sensations (tingling, pins and needles, numbness, itching) and the 
other 3 questions relate to a neurological examination in the painful area (hypoesthesia to touch and 
prick using disposable examination pins and allodynia to brushing). The scoring is based on a yes (1 
point) or no (0 point) answer and each question is equally weighted. A score ≥4 has a high sensitivity 
(80%) and specificity (92%) for PDPN20. The questionnaire was administered by the investigator 
spoken in either English or Arabic. Previously diagnosed PDPN was self-reported. Medications for 
painful neuropathy were recorded. 
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Impaired vibration perception assessment 
Vibration perception threshold (VPT) was measured bilaterally on the pulp of the large toe using a 
Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK). The strength 
of the vibration stimulus was gradually increased from null intensity to a value in voltage at which 
vibration was first detected by the participant. The test was repeated three times and the average 
value was recorded. The range for VPT readings is 1 to 50V. Iimpaired vibration perception was 
defined on a mean VPT ≥15V 22, 23. 
 
Statistical analysis 
Patients’ demographic and clinical characteristics were summarized using means and standard 
deviations for numeric variables and frequency distribution for categorical variables. Variables were 
compared between patients with and without PDPN using an unpaired t-test or Mann-Whitney test 
when the distribution was highly skewed for numeric variables and the Chi-squared test or Fisher’s 
exact test when expected cell counts fell below 5 for categorical variables.  
Binary and multiple logistic regression analysis was performed with age, duration of diabetes, 
diabetic neuropathy, gender, poor glycemic control, hypertension, obesity, physical activity, 
smoking, proteinuria and ethnic groups as independent variables, and PDPN as the dependent 
variable. The multiple logistic regression model included all variables with p-value of 0.10 or less at 
the bivariate level. Adjusted odds ratios and their corresponding 95% confidence intervals are 
presented.  
Demographic and clinical characteristics of the patients were compared between the different 
ethnic groups using the chi-square test for categorical variables such as hypertension and one-way 
ANOVA for numeric variables such as age. Multiple comparisons when needed were done using the 
Bonferroni’s method.  
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All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). A two-tailed P value 
of ≤0.05 was considered significant. 
 
Results 
Prevalence of PDPN 
The cohort (n=1095) was aged 20 to 86 years (mean [SD], 54.3 [11.4]), 60.6% were male. The clinical 
and demographic characteristics of T2DM subjects with and without painful diabetic peripheral 
neuropathy (PDPN) are compared in Table 1. The prevalence of PDPN was 34.5% (95% CI: 31.7%-
37.3%). 80.2% of the subjects with PDPN had not been previously diagnosed with this condition and 
86.0% had not been treated.  
 
Factors associated with PDPN 
Subjects with PDPN had a higher mean age (P<0.0001), duration of diabetes (P<0.0001), HbA1c 
(P=0.02), systolic blood pressure (P<0.001), weight (P<0.0001) and BMI (P<0.0001), compared to 
subjects without PDPN. Vibration perception threshold (VPT) was significantly higher (17.4V vs 9.8V, 
P<0.0001). Total cholesterol, triglycerides, HDL, LDL and diastolic blood pressure were comparable 
between the two groups. Subjects with PDPN had a higher percentage of subjects with impaired 
vibration perception (60.9% vs 23.2%, P<0.0001), a greater proportion of females (39.3% vs 31.3%, 
P<0.01), poorer glycemic control (39.6% vs 32.4%, P<0.05), more hypertension (39.0% vs 28.5%, 
P=0.001), greater proportion with proteinuria (48.4% vs 32.9%, P<0.01), more obesity (39.8% vs 
26.7%, P<0.0001) and a lower percentage of those undertaking physical activity (25.5% vs 36.8%, 
P=0.001).  
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Logistic regression analysis showed that five factors were independently and significantly associated 
with PDPN (Table 2). Impaired vibration perception adjusted odds ratio (AOR)=4.42 (95%CI: 2.92-
6.70), smoking AOR=2.43 (95%CI: 1.43-4.15), obesity AOR=1.74 (95%CI: 1.13-2.66), being female 
AOR=1.65 (95%CI: 1.03-2.64) and duration of diabetes =1.08 (95%CI: 1.05-1.11) were associated with 
PDPN. Age, poor glycemic control, hypertension, physical activity, proteinuria and ethnicity showed 
no association with PDPN. 
 
Ethnicity and PDPN 
The prevalence of PDPN differed between ethnic groups (Figure 1 and Table 3). Qataris (45.3%) and 
other Arabs (35.7%) had a higher prevalence of PDPN compared to South Asians (25.8%). However, 
the prevalence of impaired vibration perception was comparable between ethnic groups. The 
prevalence of obesity was comparable between Qataris (66.8%) and other Arabs (70.9%), but 
significantly higher than in South Asians (34.2%). The percentage of Qataris (20.8%) and other Arabs 
(35.5%) who undertook physical activity was significantly lower than in South Asians (54.3%). The 
percentage of Qataris with proteinuria was significantly higher than in South Asians (9.4% vs 3.0%) 
and comparable with other Arabs and other ethnicities. Qataris were significantly older than other 
Arabs, South Asians and other ethnicities (58.2 vs 53.8 vs 51.8 and 52.5 years, respectively) and had 
a significantly longer duration of diabetes (13.4 vs 9.1 vs 8.1 and 9.9 years, respectively). The 
percentage of Qataris with hypertension was significantly higher than other Arabs (65.3% vs 53.9%). 
There were significantly less smokers amongst Qataris compared to other Arabs (10.4% vs 23.9%).  
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Discussion 
This is the first large observational study to establish the prevalence of painful diabetic peripheral 
neuropathy (PDPN) and its associated factors in secondary care in Qatar. PDPN occurs in 
approximately one third of patients with T2DM, however, alarmingly, 4/5 had not been previously 
diagnosed or treated. PDPN, a manifestation of small fiber damage24-26, occurred in more than one in 
four patients without impaired vibration perception, and in one in two patients with impaired 
vibration perception. Impaired vibration perception, obesity and smoking were associated with 
PDPN. Arabs also have a higher prevalence of PDPN compared to Asians. This may be attributed to 
the higher percentage of women and obesity, and a lower percentage undertaking physical activity 
in the Arab population. 
 
The prevalence of PDPN in T2DM patients in Qatar was lower than previous studies from the MENA 
region, even though they also used the Douleur Neuropathique 4 (DN4) pain questionnaire and 
showed that the prevalence of PDPN was 65.3% in Saudi Arabia6, 61.3% in Egypt5, 57.5% in Jordan, 
53.9% in Lebanon and 37.1% in United Arab Emirates and Kuwait. This difference could be attributed 
to different populations and control of various risk factors, although age, duration of diabetes and 
the percentage of those with obesity were comparable to this study. However, the percentage of 
those with poor glycemic control in Saudi Arabia was higher compared to the current study (59.5% 
vs 39.6%)27. Poor glycemic control is common in the Middle East 27-30 and has been reported to be a 
significant risk factor for both DPN and PDPN15, 16. In the UK, the prevalence of PDPN in T2DM 
patients is lower (21.5% - 26.4%) than in Qatar4, 10 and may be attributed to a lower HbA1c (7.26% vs 
8.14%) and shorter duration of diabetes (4-8 years vs 10.1 years). One of the earlier UK studies 10 
was conducted in patients with T1DM and T2DM in primary care and the prevalence of PDPN is 
known to be lower in primary care12 and in T1DM patients1, 4, 7.  
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The physical quality of life of patients with PDPN decreases at a significantly faster rate over 3 years 
compared to T2DM patients without PDPN3. Patients with PDPN are also at high risk for depression, 
anxiety and sleep disturbance2. However, the under-diagnosis and treatment of PDPN continues to 
pose a considerable problem for patients. Other studies have also reported that a large proportion 
of patients with PDPN were not diagnosed, 61.5% in Germany7 and 12.5% in the UK8. Major hurdles 
limiting the diagnosis of PDPN are that patients with painful symptoms do not attribute them to 
diabetes and fail to report them to their physician8, 9 and of course screening is not currently 
advocated for PDPN, only for those at high risk of foot ulceration 31. Given that we have identified 
age, duration of diabetes and the presence of impaired vibration perception as major determinants 
for PDPN1, 5, 6, 10 one could advocate screening for PDPN in at least diabetic patients who are older, 
have a longer duration of diabetes and impaired vibration perception. Furthermore, we have 
identified that obesity is associated with PDPN, which has also been reported in some1, 5, 7, 12, but not 
other studies 6, 11. Low physical activity has been reported as a risk factor13, 14, but in this study we 
show no association after adjusting for other risk factors. Smoking has also been associated with 
PDPN in some4, 12 but not other studies1, 4-6, 11. Improved glycemic control reduces the development 
and progression of DPN in T1DM32, but has shown limited benefit in T2DM33. Low HDL cholesterol, 
raised LDL cholesterol and triglycerides have been independently associated with PDPN1. Creatinine 
is associated with PDPN, whilst albuminuria13 and proteinuria have no association. A previous study 
of subjects with pre-diabetes showed that lifestyle intervention reduced neuropathic symptoms and 
improved small fiber function and structure14. 
The prevalence of painful neuropathic symptoms4 and PDPN9 differs between ethnic groups. In our 
previous study in the UK 4, we showed that South Asians were 50% more likely to have painful 
neuropathic symptoms compared to Europeans and Afro-Caribbeans, after adjusting for age and 
duration of diabetes. However, in the present study, South Asians had a lower prevalence of PDPN 
compared to Qatari Arabs and other Arabs, which may be attributed to a lower proportion with 
obesity, less women and higher physical activity in this group. Indeed this and other studies4, 5 have 
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shown that women have a 50-65% increase in the odds for PDPN. The ethnic difference may also 
reflect genetic differences in the prevalence of abnormalities in voltage gated channels on 
nociceptors in different ethnic groups34, 35. 
 
We recognise that recruiting patients with diabetes from secondary health care centers and not 
primary care centers as a major limitation of this study and limits the generalizability of the results to 
all people with diabetes in Qatar. However, those two hospitals are the only National Diabetes & 
Endocrine Centres in Qatar and the recruited participants were of diverse backgrounds. The cross 
sectional design of this study also limits the interpretation of cause and effect in relation to risk 
factors. The strength of this study is the large sample size and the inclusion of a wide range of risk 
factors to identify those associated independently with PDPN. Furthermore, PDPN was diagnosed 
using the DN4 questionnaire, which has been validated in Arabic 21 and used in other studies in the 
MENA region to establish the prevalence of PDPN 5, 6.  
In conclusion, one in three patients with T2DM attending secondary care in Qatar have PDPN. It 
remains a neglected complication of diabetes as ~80% of patients were not diagnosed or treated for 
this condition. Impaired vibration perception, obesity and smoking are associated with PDPN, 
suggesting that patients with these risk factors should be screened for PDPN and treated for relief of 
symptoms and with life style interventions to limit progression. 
Acknowledgement: 
We thank all the participants for their efforts, will and commitment to be involved in the study. 
 
Disclosure: 
No conflict of interest 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Research funding:  
Funding source: Qatar National Research Fund, Funding ID: Grant BMRP-5726113101 Funding 
source: Pfizer Gulf FZ LLC, Funding ID: W1230787 
References 
1. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of 
peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients 
attending hospital outpatients clinics. Diabetes Metab. 2009;35(3): 206-213. 
2. Bohlega S, Alsaadi T, Amir A, et al. Guidelines for the pharmacological treatment of 
peripheral neuropathic pain: expert panel recommendations for the middle East region. J Int Med 
Res. 2010;38(2): 295-317. 
3. daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful 
diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. 
Pain Med. 2011;12(1): 118-126. 
4. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of 
painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes 
Care. 2011;34(10): 2220-2224. 
5. Jambart S, Ammache Z, Haddad F, et al. Prevalence of painful diabetic peripheral neuropathy 
among patients with diabetes mellitus in the Middle East region. J Int Med Res. 2011;39(2): 366-377. 
6. Halawa MR, Karawagh A, Zeidan A, Mahmoud AE, Sakr M, Hegazy A. Prevalence of painful 
diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr 
Med Res Opin. 2010;26(2): 337-343. 
7. Ziegler D, Landgraf R, Lobmann R, et al. Painful and painless neuropathies are distinct and 
largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). 
Diabetes research and clinical practice. 2018;139: 147-154. 
8. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic 
painful peripheral neuropathy in an urban community: a controlled comparison of people with and 
without diabetes. Diabet Med. 2004;21(9): 976-982. 
9. Eichholz M, Alexander AH, Cappelleri JC, et al. Perspectives on the impact of painful diabetic 
peripheral neuropathy in a multicultural population. Clinical diabetes and endocrinology. 2017;3: 12. 
10. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful 
diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7): 1518-1522. 
11. Jacovides A, Bogoshi M, Distiller LA, et al. An epidemiological study to assess the prevalence 
of diabetic peripheral neuropathic pain among adults with diabetes attending private and 
institutional outpatient clinics in South Africa. J Int Med Res. 2014;42(4): 1018-1028. 
12. Aslam A, Singh J, Rajbhandari S. Prevalence of Painful Diabetic Neuropathy Using the Self-
Completed Leeds Assessment of Neuropathic Symptoms and Signs Questionnaire in a Population 
with Diabetes. Can J Diabetes. 2015;39(4): 285-295. 
13. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A, Group KS. Prevalence and risk 
factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The 
KORA Myocardial Infarction Registry. Eur J Pain. 2009;13(6): 582-587. 
14. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. 
Diabetes Care. 2006;29(6): 1294-1299. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
15. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the 
U.S. population. Diabetes Care. 1993;16(11): 1446-1452. 
16. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14(1): 
23-29. 
17. Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in 
the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain. 
2010;11(11): 1129-1135. 
18. Moser M. World Health Organization-International Society of Hypertension Guidelines for 
the Management of Hypertension-Do These Differ From the U.S. Recommendations? Which 
Guidelines Should the Practicing Physician Follow? J Clin Hypertens (Greenwich). 1999;1(1): 48-54. 
19. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. 
World Health Organ Tech Rep Ser. 2000;894: i-xii, 1-253. 
20. Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a 
screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29(5): 578-
585. 
21. Harifi G, Ouilki I, El Bouchti I, et al. Validity and reliability of the Arabic adapted version of 
the DN4 questionnaire (Douleur Neuropathique 4 Questions) for differential diagnosis of pain 
syndromes with a neuropathic or somatic component. Pain Pract. 2011;11(2): 139-147. 
22. Wiles PG, Pearce SM, Rice PJ, Mitchell JM. Vibration perception threshold: influence of age, 
height, sex, and smoking, and calculation of accurate centile values. Diabet Med. 1991;8(2): 157-161. 
23. Garrow AP, Boulton AJ. Vibration perception threshold--a valuable assessment of neural 
dysfunction in people with diabetes. Diabetes Metab Res Rev. 2006;22(5): 411-419. 
24. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small 
nerve fibers in diabetes. Diabetes Care. 2006;29(4): 883-887. 
25. Vlckova-Moravcova E, Bednarik J, Belobradkova J, Sommer C. Small-fibre involvement in 
diabetic patients with neuropathic foot pain. Diabet Med. 2008;25(6): 692-699. 
26. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in 
human diabetic neuropathy. Diabetes. 2007;56(8): 2148-2154. 
27. Akbar DH, Mira SA, Zawawi TH, Malibary HM. Subclinical diabetic neuropathy. A common 
complication in Saudi diabetics. Neurosciences (Riyadh). 2000;5(2): 110-114. 
28. Youssef AA, El Mahalli AA, Akl OA, Zaghloul AA. Quality of diabetes care in primary care 
setting in egypt: an example of health sector reform in developing countries. J Egypt Public Health 
Assoc. 2006;81(5-6): 301-320. 
29. Uddin I, Ahmad TJ, Kurkuman AR, Iftikhar R. Diabetes education: its effects on glycemic 
control. Ann Saudi Med. 2001;21(1-2): 120-122. 
30. Habib SS, Aslam M. Risk factors, knowledge and health status in diabetic patients. Saudi Med 
J. 2003;24(11): 1219-1224. 
31. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by 
the American Diabetes Association. Diabetes Care. 2017;40(1): 136-154. 
32. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular 
complications in diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2): 90-96. 
33. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing 
and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012(6): CD007543. 
34. Wadhawan S, Pant S, Golhar R, et al. NaV channel variants in patients with painful and 
nonpainful peripheral neuropathy. Neurology Genetics. 2017;3(6): e207. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
35. Blesneac I, Themistocleous AC, Fratter C, et al. Rare NaV1.7 variants associated with painful 
diabetic peripheral neuropathy. International journal of endocrinology. 2018;159(3): 469-480. 
 
Figure 1. Prevalence of painful diabetic peripheral neuropathy between ethnic groups. 
 
Table 1. Demographic characteristics of adults with T2DM stratified by painful diabetic peripheral 
neuropathy (PDPN) status. Patients’ demographic and clinical characteristics summarized using 
means and standard deviations for numeric variables and frequency distribution for categorical 
variables. Continues parametric and non-parametric variables were compared using unpaired t-test 
and (*) Mann-Whitney test, respectively. Categorical variables were compared using x2. 
 
 Painful diabetic neuropathy
P value No Yes
n (%) 717 (65.5) 378 (34.5) N/A 
Age, years, mean (SD) 52.6 ± 11.4 57.5 ± 10.7 <0.0001*
Gender, n (%) Male 453 (68.7) 206 (31.3) <0.01 
 Female 261 (60.7) 169 (39.3)  
Diabetes duration, years, mean (SD) 8.2 ± 7.0 13.6 ± 7.9 <0.0001*
HbA1c, mean (SD) % 8.0 ± 2.0 8.4 ± 2.0 0.02 
   mmol/mol 64.9 ± 22.3 67.9 ± 21.8 0.02 
Poor glycemic control Yes 174 (60.4) 114 (39.6) <0.05 
    No 474 (67.6) 227 (32.4)  
Cholesterol, mmol/l, mean (SD) 4.5 ± 1.2 4.4 ± 1.1 NS 
Triglyceride, mmol/l, mean (SD) 1.9 ± 1.3 1.7 ± 1.0 NS* 
HDL, mmol/l, mean (SD) 1.3 ± 0.2 1.1 ± 0.0 NS 
LDL, mmol/l, mean (SD) 2.6 ± 0.0 2.5 ± 0.0 NS 
Systolic blood pressure, mmHg, mean (SD) 131.1 ± 17.7 135.4 ± 18.3 <0.001 
Diastolic blood pressure, mmHg, mean (SD) 78.5 ± 10.5 77.6 ± 9.5 NS 
Hypertension, n (%) Yes 371 (61.0) 237 (39.0) 0.001 
 No 294 (71.5) 117 (28.5)  
Weight, Kg, mean (SD) 83.4 ± 21.4 87.6 ± 18.6 <0.0001*
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BMI, Kg/m2, mean (SD) 30.7 ± 6.8 32.7 ± 7.0 <0.0001 
Obesity, n (%), n (%) Yes 314 (60.2) 208 (39.8) <0.0001 
 No 318 (73.3) 116 (26.7)  
Physical activity, n (%) Yes 240 (74.5) 82 (25.5) 0.001 
 No 330 (63.2) 192 (36.8)  
Smoking, n (%) Yes 107 (69.0) 48 (31.0) NS 
 No 501 (67.2) 244 (32.8)  
Proteinuria, n (%) Yes 33 (51.6) 31 (48.4) <0.01 
 No 300 (67.1) 147 (32.9)  
Vibration perception threshold, V, mean (SD) 9.8 ± 7.5 17.4 ± 10.6 <0.0001 
Impaired vibration perception, n 
(%) 
 
Yes 126 (39.1) 196 (60.9) <0.0001 
 No 586 (76.8) 177 (23.2)  
Previously diagnosed with PDPN, n (%) 28 (4.0) 73 (19.8) <0.0001 
Treated for PDPN, n (%) 22 (3.1) 53 (14.0) <0.0001 
Ethnic groups, n (%) Qataris 181 (54.7) 150 (45.3) <0.0001 
   Other Arabs 196 (64.3) 109 (35.7)  
   South Asians 299 (74.2) 104 (25.8)  
   Others 41 (73.2) 15 (26.8)  
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Table 2. Logistic regression analysis between painful diabetic peripheral neuropathy and risk factors. 
Outcome variable: Painful diabetic peripheral neuropathy. Independent variables: Age, duration of 
diabetes, impaired vibration perception, female, poor glycemic control, hypertension, obesity, 
physical activity, smoking, proteinuria and ethnic groups were considered in the fitted model with a 
P value ≤0.05. 
 
OR (95% CI) P value 
Age 1.01 (0.99 - 1.03) NS
Duration of diabetes 1.08 (1.05 - 1.11) <0.0001 
impaired vibration perception 4.42 (2.92 - 6.70) <0.0001 
Female 1.65 (1.03 - 2.64) <0.05 
Poor glycemic control 1.40 (0.93 - 2.11) NS
Hypertension 1.16 (0.77 - 1.76) NS
Obesity 1.74 (1.13 - 2.66) <0.01 
Physical activity 0.83 (0.55 - 1.26) NS
Smoking 2.43 (1.43 - 4.15) 0.001 
Proteinuria 1.04 (0.51 - 2.16) NS
Ethnic groups 
Qataris 1 NS
Other Arabs 1.05 (0.64 - 1.73) NS
South Asians 0.95 (0.57 - 1.59) NS
Others 0.81 (0.31 - 2.07) NS
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Table 3. Differences in the prevalence of painful diabetic peripheral neuropathy and other risk 
factors between different ethnic groups. a,b,c,d within each row, columns with similar letters are not 
statistically significant and those with different letters are significantly different. 
 
 
 
 
 
 
 
 
  
 Qataris Other Arabs South Asians Others 
n 331 305 403 56 
Painful DPN, n (%) 150 (45.3)a 109 (35.7)a 104 (25.8)b 15 (26.8)ab
Age, years, mean (SD) 58.2 (12.0)a 53.8 (11.7)b 51.8 (9.7)b 52.5 (10.5)b
Duration of diabetes, years, mean (SD) 13.4 (7.8)a 9.1 (7.2)b 8.1 (7.0)b 9.9 (8.4)b
Impaired vibration perception, n (%) 108 (33.0)a 91 (30.0)a 102 (25.6)a 21 (37.5)a
Female, n (%) 211 (64.1)a 109 (35.9)b 89 (22.3)c 21 (39.5)bc
Poor glycemic control, n (%) 100 (33.8)a 86 (31.5)a 152 (41.4)a 21 (39.6)a
Hypertension, n (%) 196 (65.3)a 153 (53.9)b 229 (59.9)ab 30 (56.6)ab
Obesity, n (%) 185 (66.8)ab 188 (70.9)b 125 (34.2)c 24 (49.0)ac
Physical activity, n (%) 52 (20.8)a 87 (35.5)b 170 (54.3)c 13 (36.1)abc
Smoking, n (%) 27 (10.4)a 62 (23.9)b 57 (16.9)ab 9 (20.5)ab
Proteinuria, n (%) 31 (9.4)a 15 (4.9)a,b 12 (3.0)b 6 (10.7)a
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